Xenomics, Inc. (XNOM.PK) is focused on the testing of urine samples for transrenal DNA. Before the Company’s scientists developed its patented Tr-DNA testing methodology, the medical diagnostic field mostly relied on blood samples for DNA testing.
The Company was incorporated in Florida by Dr. David Tomei and Dr. Samuel Umansky after years of leading research in Apoptosis and Genetically Programmed Cell Death. Xenomics is unique as they use the simple collection of urine to detect and monitor for tumors and infectious diseases.
Xenomics’ technology also has the ability to detect both HIV and common tuberculosis infections simutaneously. Before this discovery it was believed that it is impossible to detect such DNA in urine. The Company’s revolutionary discovery that a trace amount of DNA can actually be detected has opened a new field of biomedical testing.